|
|
| Line 1: |
Line 1: |
| {{Product | | {{Product |
| |description=Cell permeable compound - MitoKit-CII, 2 vials; 1 vial of plasma membrane-permeable succinate-nv (Snv; NV118; 25 mg) and 1 vial of plasma membrane-permeable malonate-nv (Mnanv; NV161; 10 mg). | | |description=[[File:MITOKIT-CII.jpg|right|180px]]Cell permeable compound - MitoKit-CII, 2 vials; 1 vial of plasma membrane-permeable succinate-nv (Snv; NV118; 25 mg) and 1 vial of plasma membrane-permeable malonate-nv (Mnanv; NV161; 10 mg). |
| |product id=60200-01 | | |product id=60200-01 |
| |product type=O2k | | |product type=O2k |
| |info= [[MitoKit-CII MitoPedia]] | | |info= [https://www.oroboros.at/index.php/product/mitokit-cii/ '''Product details and purchasing information'''] |
| |product image=[[File:MITOKIT-CII.jpg|right|180px]] | | |product image= |
| }} | | }} |
|
| |
|
| __TOC__
| | == Additional resources == |
|
| |
|
| | » [[MitoKit-CII MitoPedia]] |
|
| |
|
|
| |
|
| == Compounds of MitoKit-CII ==
| |
| :::: The MitoKit-CII consists of the first generation of NeuroVive Pharmaceutical AB's cell permeable succinate and malonate prodrugs. The MitoKit-CII was developed to stimulate (succinate-nv) or inhibit (malonate-nv) the Complex II of the respiratory electron transfer system in living cells, and will expand the toolbox for evaluating the role of mitochondria in disease.
| |
|
| |
| :::: The MitoKit-CII is composed of the following compounds:
| |
|
| |
| ::::* '''Cell permeable compound [[MitoKit-CII/Succinate-nv]]''', Snv
| |
| ::::: Description: Succinate prodrug: C<sub>10</sub>H<sub>14</sub>O<sub>8</sub>, Molecular weight 262.2 g.mol<sup>-1</sup>
| |
| ::::: Aliquots of 25 mg
| |
|
| |
|
| |
| ::::* '''Cell permeable compound [[MitoKit-CII/Malonate-nv]]''', Mnanv
| |
|
| |
| ::::: Description: Malonate prodrug: C<sub>9</sub>H<sub>12</sub>O<sub>8</sub>, Molecular weight 248.2 g.mol<sup>-1</sup>
| |
| ::::: Aliquots of 10 mg
| |
|
| |
|
| |
| ::::* Reference
| |
| :::::: Ehinger JK, Piel S, Ford R, Karlsson M, Sjövall F, Frostner EÅ, Morota S, Taylor RW, Turnbull DM, Cornell C, Moss SJ, Metzsch C, Hansson MJ, Fliri H, Elmér E (2016) Cell-permeable succinate prodrugs bypass mitochondrial Complex I deficiency. Nat Commun 7:12317. [[Ehinger 2016 Nat Commun|»Bioblast link«]] - ''Original publication introducing Mito-CII''.
| |
|
| |
|
| |
| == Expiry date of MitoKit-CII compounds (according to NeuroVive) ==
| |
|
| |
|
| |
| ::: Before preparation
| |
| ::::* 3 years in -80° C
| |
| ::::* 1 year in -20° C
| |
|
| |
|
| |
| ::: Prepared
| |
| ::::* In DMSO solution
| |
| ::::::* at room temperature: 24 h
| |
| ::::::* at -20 °C: for 6 months
| |
|
| |
|
| |
| ::: CAS-Numbers
| |
| ::::* MitoKit-CII/Succinate-nv: 1592635-33-0
| |
| ::::* MitoKit-CII/Malonate-nv: 1432752-62-9
| |
|
| |
|
|
| |
|
